ClinicalTrials.gov
public full text
Public Domain
Low-dose Interleukin-2 Treatment on Polymyalgia Rheumatica
This study aims to explore the clinical and immunological efficacy of low-dose Interleukin-2 (IL-2) on polymyalgia rheumatica.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Short Term Efficacy of a Starting Dose of 12.5 mg of Prednisone in Polymyalgia Rheumatica Patients#813923
- Effectiveness of Interdisciplinary Care Compared to Usual Care in Patients With Immune-Mediated Inflammatory Diseases#1153314
- Clinical spectrum and diagnostic outcomes of patients with suspected inflammatory rheumatic disease in the emergency department: a retrospective study.#266876
- Low Dose Naltrexone (LDN) Immune Monitoring#1151259
- Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica#811651
Record · ID 1260478
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive